The Efficacy of Vedolizumab, an α4β7 Integrin Antibody, in Crohn's Disease and Ulcerative Colitis

Kim, Eun Sun

doi:2013.11.4.325

Search: Intest Res Search

CLOSE

Intest Res > Volume 11(4); 2013 > Article

Selected Summary

Intestinal Research 2013;11(4):325-326.
DOI: https://doi.org/10.5217/ir.2013.11.4.325 Published online October 30, 2013.

The Efficacy of Vedolizumab, an α4β7 Integrin Antibody, in Crohn's Disease and Ulcerative Colitis

Eun Sun Kim

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Digestive Disease and Nutrition, Korea University College of Medicine, Seoul, Korea

Abstract

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis (N Engl J Med 2013;369:699-710) Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease (N Engl J Med 2013;369:711-721)

TOOLS

PDF Links
Full text via DOI
Download Citation

Share :

METRICS

0 Crossref
Scopus
2,075 View
15 Download

We recommend

ABOUT

ARTICLE & TOPICS

Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES

EDITORIAL POLICY

AUTHOR INFORMATION

Editorial Office: Room 310, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145 Fax: +82-2-957-6146 E-mail: thekasid@irjournal.org